08:09 EST Kura Oncology (KURA) drops 11% to $8.07 after leukemia update, BTIG downgrade
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Scotiabank would buy Kura on weakness despite KOMET-001 uncertainty
- Kura Oncology downgraded to Neutral from Buy at BTIG
- Kura Oncology price target raised to $40 from $37 at H.C. Wainwright
- Closing Bell Movers: Semis down sharply after results
- Kura, Kyowa Kirin announce KOMET-001 results, FDA feedback for trial designs
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue